SecBot SecBot

HUMAW

Humacyte, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001818382 Biotech & Drug Discovery
—
Market cap
$250.0K
Nano cap
1 year
−73.7%
from $1.70 · Oct 28
30 days
−18.4%
from $0.5470
52-week range
$0.3540–1.70
−74% from high · low Oct 14
Avg volume 20D
6.50M
Oct 15 spike 20.79M
Short interest
2.7K
≈0.0% of shares · −11.0%
Days to cover
1.0
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
2
analyzed by SecBot
SecBot read BULLISH 2 reports · latest
Balance 0 bearish · 2 bullish oldest → newest, height = score
Avg score ·High conf. 2/2
Strongest BULLISH Humacyte reported positive interim results from its V012 Phase 3 study of the ATEV in female dialysis access…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • Short sellersSTEADY

    Short interest −11.0% to 2.7K shares. 1.0 days to cover, ≈0.0% of shares.

  • TrendDOWNTREND

    17% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
WOLVERINE ASSET MANAGEMENT LLCADD48,429$465.00
SUSQUEHANNA INTERNATIONAL GROUP, LLPNEAR_EXIT10,059$97.00
WOLVERINE ASSET MANAGEMENT LLCTRIM36,860$3.5K
UBS Group AGDOUBLED894$84.00
WOLVERINE ASSET MANAGEMENT LLCADD50,011$13.3K
WOLVERINE ASSET MANAGEMENT LLCTRIM32,035$58.3K

Quarterly 13F filings are due 45 days after each quarter ends.

Washington

Corporate Lobbying

12 lobbying filings and 0 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$1.1M
Next Q———$1.8M
Current FY———$3.5M
Next FY———$21.7M
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Aug 26, 2026
Listing
Delisted: HUMAW — removed from the Nasdaq symbol directory
Humacyte, Inc. - Warrant

Short side

FINRA· Aug 14, 2026
2,733
shares short
-11.0%
vs prior settlement
1.0
days to cover
≈0.0%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 26, 2026 Listing status
Delisted: HUMAW — removed from the Nasdaq symbol directory
Humacyte, Inc. - Warrant
Jun 30, 2026 Inst.
WOLVERINE ASSET MANAGEMENT LLC — ADD
48,429 shares ($465.00)
Jun 30, 2026 Inst.
SUSQUEHANNA INTERNATIONAL GROUP, LLP — NEAR_EXIT
10,059 shares ($97.00)
Jun 10, 2026 SEC
Humacyte reported positive interim results from its V012 Phase 3 study of the ATEV in female dialysis access patients…
8-K — Impact 7/10
Apr 24, 2026 SEC
Humacyte has reacquired global commercial rights to its Symvess product from Fresenius, regaining full control over…
8-K — Impact 7/10

SecBot reports

2 filings · 2 bullish · 0 bearish
All HUMAW filing & press-release reports (2)